APP and Alzheimer disease: Cumulatively, these two factors substantially accelerate, in comparison with wild-type AβPP carriers, the crossing of the T1 threshold by AβPP-derived iAβ and the consequent commencement of the second AD stage in carriers of the second category of FAD mutations.